Jefferies Financial Group Inc. Makes New $133,000 Investment in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

Jefferies Financial Group Inc. bought a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $133,000.

A number of other institutional investors have also modified their holdings of the stock. Cubist Systematic Strategies LLC grew its position in Eton Pharmaceuticals by 422.9% in the 4th quarter. Cubist Systematic Strategies LLC now owns 43,239 shares of the company’s stock valued at $576,000 after buying an additional 34,970 shares during the last quarter. Balyasny Asset Management L.P. purchased a new position in Eton Pharmaceuticals during the 4th quarter worth $158,000. Bank of America Corp DE lifted its stake in shares of Eton Pharmaceuticals by 5,422.4% in the 4th quarter. Bank of America Corp DE now owns 11,100 shares of the company’s stock worth $148,000 after acquiring an additional 10,899 shares during the period. 683 Capital Management LLC acquired a new stake in shares of Eton Pharmaceuticals in the 4th quarter worth $919,000. Finally, Jane Street Group LLC boosted its holdings in shares of Eton Pharmaceuticals by 328.6% in the fourth quarter. Jane Street Group LLC now owns 64,323 shares of the company’s stock valued at $857,000 after acquiring an additional 49,317 shares in the last quarter. Institutional investors and hedge funds own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

ETON has been the subject of a number of recent analyst reports. B. Riley restated a “buy” rating and issued a $26.00 price objective (up previously from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday. HC Wainwright reissued a “buy” rating and issued a $33.00 price target on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th. Finally, Craig Hallum upped their price objective on Eton Pharmaceuticals from $26.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, May 14th.

Eton Pharmaceuticals Stock Down 3.9%

Shares of ETON opened at $18.93 on Monday. Eton Pharmaceuticals, Inc. has a 52-week low of $3.18 and a 52-week high of $21.48. The company has a 50-day simple moving average of $14.82 and a 200-day simple moving average of $13.96. The company has a market capitalization of $507.66 million, a PE ratio of -86.05 and a beta of 1.22.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The company had revenue of $17.28 million for the quarter, compared to analyst estimates of $14.33 million. On average, research analysts anticipate that Eton Pharmaceuticals, Inc. will post -0.14 EPS for the current year.

Eton Pharmaceuticals Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.